利司那肽：肠促胰岛素疗法中胰高血糖素样肽-1受体激动剂类别的新成员。
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.
作者信息
Shaefer Charles F
机构信息
University Health Systems-Primary Care and Medical College of Georgia, Augusta University, Augusta, GA.
出版信息
Clin Diabetes. 2016 Apr;34(2):81-5. doi: 10.2337/diaclin.34.2.81.
Abstract
In Brief In the past decade, various incretin-based therapies have emerged in clinical practice. These drugs, including dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists lower A1C with weight-neutral or weight-lowering effects and a relatively lower risk of hypoglycemia. This article provides a review of lixisenatide, a once-daily GLP-1 receptor agonist for the treatment of type 2 diabetes.
摘要
简而言之，在过去十年中，多种基于肠促胰岛素的疗法已出现在临床实践中。这些药物，包括二肽基肽酶-4抑制剂和胰高血糖素样肽1（GLP-1）受体激动剂，可降低糖化血红蛋白（A1C）水平，具有体重中性或减重作用，且低血糖风险相对较低。本文对利司那肽进行综述，这是一种每日一次用于治疗2型糖尿病的GLP-1受体激动剂。
相似文献
1
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.利司那肽：肠促胰岛素疗法中胰高血糖素样肽-1受体激动剂类别的新成员。
Clin Diabetes. 2016 Apr;34(2):81-5. doi: 10.2337/diaclin.34.2.81.
2
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.基于肠降血糖素的 2 型糖尿病治疗药物：对疗效、安全性和患者满意度的直接比较的综述。
Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22.
3
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.胰岛素加肠促胰岛素：一种用于2型糖尿病的降糖策略。
World J Diabetes. 2014 Feb 15;5(1):40-51. doi: 10.4239/wjd.v5.i1.40.
4
Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.利西那肽治疗 2 型糖尿病的作用机制和临床疗效。
Adv Ther. 2013 Feb;30(2):81-101. doi: 10.1007/s12325-013-0009-4. Epub 2013 Feb 13.
5
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.肠促胰岛素疗法：强调胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂作用模式的共同特征与差异
Diabetes Obes Metab. 2016 Mar;18(3):203-16. doi: 10.1111/dom.12591. Epub 2016 Jan 5.
6
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.GLP-1 受体激动剂和二肽基肽酶-4 抑制剂作为二甲双胍的附加疗法在 2 型糖尿病患者中的血糖疗效：综述和荟萃分析。
Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24.
7
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂的心血管作用和临床结局。
Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136.
8
An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.每周一次胰高血糖素样肽-1 受体激动剂概述——现有疗效和安全性数据及未来展望。
Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5.
9
Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.比较每周一次司美格鲁肽与基于肠促胰岛素的疗法治疗 2 型糖尿病患者：系统评价和荟萃分析。
Diabetes Metab. 2019 Apr;45(2):102-109. doi: 10.1016/j.diabet.2018.09.002. Epub 2018 Sep 20.
10
Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.区分肠促胰岛素治疗：2 型糖尿病的多靶点方法。
J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21.
引用本文的文献
1
Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.2型糖尿病病程对接受基础胰岛素治疗的亚洲患者加用利司那肽疗效和安全性的影响：一项汇总分析
Diabetes Ther. 2023 Apr;14(4):653-669. doi: 10.1007/s13300-023-01369-6. Epub 2023 Feb 21.
2
A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.一项关于利西那肽在 2 型糖尿病儿童和青少年中的药代动力学、药效学和安全性的研究。
Pediatr Diabetes. 2022 Sep;23(6):641-648. doi: 10.1111/pedi.13343. Epub 2022 Apr 24.
3
Lixisenatide: A New Option for Managing Type 2 Diabetes.利司那肽：治疗2型糖尿病的新选择。
J Pharm Technol. 2017 Oct;33(5):195-203. doi: 10.1177/8755122517711958. Epub 2017 Jun 7.
4
Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor.基于配体的药物设计以鉴定 IGF-1R 拮抗剂及氟维司群作为潜在抑制剂的体外验证
PLoS One. 2018 May 22;13(5):e0196312. doi: 10.1371/journal.pone.0196312. eCollection 2018.
本文引用的文献
1
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.每日一次利司那肽对2型糖尿病患者胃排空的影响——与餐后血糖的关系
Regul Pept. 2013 Aug 10;185:1-8. doi: 10.1016/j.regpep.2013.04.001. Epub 2013 May 9.
2
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).对于基础胰岛素控制不佳的 2 型糖尿病患者，加用每日一次的利西那肽：一项 24 周、随机、安慰剂对照比较研究（GetGoal-L）。
Diabetes Care. 2013 Sep;36(9):2489-96. doi: 10.2337/dc12-2454. Epub 2013 Apr 29.
3
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).在新起始并持续滴定基础胰岛素甘精胰岛素后仍控制不佳的 2 型糖尿病患者中添加每日一次利西那肽：一项 24 周、随机、安慰剂对照研究（GetGoal-Duo 1）。
Diabetes Care. 2013 Sep;36(9):2497-503. doi: 10.2337/dc12-2462. Epub 2013 Apr 5.
4
Lixisenatide: first global approval.利西那肽：全球首次批准。
Drugs. 2013 Mar;73(4):383-91. doi: 10.1007/s40265-013-0033-3.
5
Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.利西那肽治疗 2 型糖尿病的作用机制和临床疗效。
Adv Ther. 2013 Feb;30(2):81-101. doi: 10.1007/s12325-013-0009-4. Epub 2013 Feb 13.
6
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.每日一次利西那肽与每日一次利拉鲁肽治疗二甲双胍控制不佳的 2 型糖尿病患者的药效学特征。
Diabetes Obes Metab. 2013 Jul;15(7):642-9. doi: 10.1111/dom.12076. Epub 2013 Feb 25.
7
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.度拉糖肽每周 1 次与艾塞那肽每周 1 次治疗 2 型糖尿病患者的疗效比较（DURATION-6）：一项随机、开放标签研究。
Lancet. 2013 Jan 12;381(9861):117-24. doi: 10.1016/S0140-6736(12)61267-7. Epub 2012 Nov 7.
8
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.GLP-1 激动剂治疗 2 型糖尿病：药代动力学和毒理学考虑。
Expert Opin Drug Metab Toxicol. 2013 Jan;9(1):17-29. doi: 10.1517/17425255.2013.731394. Epub 2012 Oct 24.
9
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.GLP-1 受体激动剂用于 2 型糖尿病的个体化治疗。
Nat Rev Endocrinol. 2012 Dec;8(12):728-42. doi: 10.1038/nrendo.2012.140. Epub 2012 Sep 4.
10
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).一项在亚洲 2 型糖尿病患者中进行的随机、双盲、安慰剂对照试验，评估每日一次 GLP-1 受体激动剂利西那肽在基础胰岛素联合或不联合磺脲类药物治疗血糖控制不佳的患者中的疗效（GetGoal-L-Asia）。
Diabetes Obes Metab. 2012 Oct;14(10):910-7. doi: 10.1111/j.1463-1326.2012.01618.x. Epub 2012 May 30.
Zotero 插件